TherapeuticsMD Q2 License Revenue Falls; Strategic Review Continues
TXMD has more than doubled off its 52-week low of $0.99 on light trading volume (0.4× avg).
Summary
Q2 net income dropped to $164K from $545K a year ago, driven by lower licensed product sales. The company is still evaluating strategic alternatives, including a possible merger or asset sale, with no timeline set. A CAD 500K milestone payment will hit Q3 revenue. With a market cap around $24M and a going-concern warning already disclosed, the revenue decline adds pressure to the strategic review process.
At the time of this announcement, TXMD was trading at $2.07 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $24M. The 52-week trading range was $0.99 to $2.95. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.